Healthcare
The pharmaceutical and health industry is also one of the key areas that Pan Asia Investment Holdings has always focused on over the years. Since 2015, Pan Asia Investment Holdings has been investing in this industry in various ways. These investments include the research and development of intelligent medical aids, the pharmaceutical distribution chain, and the innovation of medical services.
Rising health awareness
The COVID-19 epidemic has entered its 4th year so far since the outbreak in late 2019. The epidemic keeps recurring and is late to end. It is clear that the epidemic has had a profound impact on the development of the global biopharmaceutical industry. The world’s major economies, continue to increase their investment in the healthcare sector. All major developed countries per capita health care spending in GDP, on average, reached more than 10%. The overall trend in the pharmaceutical and health industry is increasingly favourable for long-term development.
Ageing Population
Major economies around the world are facing aging demographics, and the trend is expanding further. By 2060, Japan, the country with the most serious aging problem, will have close to 38% of its population older than 65 years old. Geriatrics, geriatric rehabilitation, geriatric care, and combined medical and nursing care are gradually emerging, home-based, day care, and inpatient care are gradually being constructed, and long-term care and care insurance will be gradually piloted and implemented in various places.
Investing in the future
Since the epidemic, Internet medicine has played an important role in the management of chronic diseases, post-operative patient follow-up management, helping families with chronic diseases to achieve online follow-up consultations and medication without leaving home, this new treatment behaviour, consumer demand is stimulated, gradually trusted by patients, Internet medical ushered in rapid growth. In this context, some pharmaceutical e-commerce head platforms have benefited significantly, and more and more hospitals have started to tilt their resources to Internet medicine.
In the coming cycle, in order to deal with the risk of security incidents caused by medical data interoperability, several governments around the world will further regulate medical data in terms of privacy protection, commercial realisation and authorised use. With the rapid development and popularisation of medical information and data, it is foreseeable that some patients with chronic diseases will truly own and publicly utilise their personal medical health data to achieve the advocated, safe and better personalised healthcare. Medical data has become a key element in the development of the healthcare industry. Managing and utilising medical data well and developing medical artificial intelligence applications based on medical data are the hot spots in the healthcare industry and the focus of future development.
Pan Asia Investment Holdings was continuously focusing on the above areas and looking for excellent investment targets. Existing partners include industry leaders such as China National Pharmaceutical Group, NC Healthcare (00754.HK) and investment partners such as Hony Capital.